- Price
- 5.76p
- Market cap
- £15m
- 1M
- -35.1%
- 3M
- -38.5%
- 1Y
- -0.6%
- P/E (trailing)
- —
- Dividend yield
- —
“the Board still anticipates reporting 2026 full year numbers in line with market expectations*. * Market expectations for the year ending 30 June 2026: revenue of £6.2 million and adjusted EBITDA of £0.7 million”
adjusted EBITDA · stated consensus £700,000
“Market expectations for the year ending 30 June 2026; revenue of £6.2 million and adjusted EBITDA of £0.7 million”
adjusted EBITDA · stated consensus £700,000
“Management expects to report unaudited revenues of between c.4.5m-4.8m1 (FY24: 1.2m), driven by a full year's trading by Dermatonics, eight months trading by Bio-Tech Solutions (BTS), as well as ongoing growth of organic sales of AxisBiotix. Revenues were slightly lower than market expectations due to timing of orders for Dermatonics and BTS, much of which occurred just after the year end.”
revenue · stated consensus £4.1m
Last 24 months of trading updates, one verdict per announcement (the headline profit measure first). Companies report these themselves and lean positive, so compare against peers: the same tag-based peer group as the Overview, counting peers with at least 2 updates and needing at least 3. Verdicts are machine-extracted; where the quoted wording clearly says otherwise, the wording is used.
“the Board still anticipates reporting 2026 full year numbers in line with market expectations*. * Market expectations for the year ending 30 June 2026: revenue of £6.2 million and adjusted EBITDA of £0.7 million”
adjusted EBITDA · stated consensus £700,000
“Market expectations for the year ending 30 June 2026; revenue of £6.2 million and adjusted EBITDA of £0.7 million”
adjusted EBITDA · stated consensus £700,000
“Management expects to report unaudited revenues of between c.4.5m-4.8m1 (FY24: 1.2m), driven by a full year's trading by Dermatonics, eight months trading by Bio-Tech Solutions (BTS), as well as ongoing growth of organic sales of AxisBiotix. Revenues were slightly lower than market expectations due to timing of orders for Dermatonics and BTS, much of which occurred just after the year end.”
revenue · stated consensus £4.1m
Last 24 months of trading updates, one verdict per announcement (the headline profit measure first). Companies report these themselves and lean positive, so compare against peers: the same tag-based peer group as the Overview, counting peers with at least 2 updates and needing at least 3. Verdicts are machine-extracted; where the quoted wording clearly says otherwise, the wording is used.